Executive Summary
In the rapidly evolving landscape of global oncology, the transition from a successful clinical trial to a successful commercial launch is fraught with systemic hurdles. A leading global biopharmaceutical company, possessing a breakthrough targeted oncology therapy, sought to expand its footprint beyond the traditional strongholds of the United States and Europe. The objective was to penetrate the high-growth, yet highly complex, markets of the Asia-Pacific (APAC) region and various Emerging Markets (LatAm, Middle East, and Southeast Asia).This case study outlines the development of an integrated, evidence-driven market access and pricing framework. By synthesizing global brand ambition with granular local realities, the strategy addressed fragmented reimbursement pathways, intense pricing pressures, and the intricate web of International Reference Pricing (IRP). The resulting roadmap prioritized speed-to-market while safeguarding the long-term global value of the asset.
Client Background: A Portfolio at a CrossroadsThe client is a Tier-1 global biopharmaceutical innovator recognized for its robust pipeline in precision medicine and oncology. Having recently secured regulatory milestones in the U.S. (FDA) and Europe (EMA) for a novel targeted therapy, the client faced a critical inflection point. While their internal infrastructure was optimized for Western markets, their experience in the "Rest of World" (RoW) territories was fragmented.
The expansion focus included two distinct but equally challenging clusters:Asia-Pacific (APAC): Specifically the "Big Four" (China, Japan, South Korea, and India), characterized by high patient volumes but drastically different Health Technology Assessment (HTA) maturities.Emerging Markets: Spanning Latin America (Brazil, Mexico), the Middle East (Saudi Arabia, UAE), and Southeast Asia (Vietnam, Indonesia). These regions represent the future of volume growth but are often hampered by volatility in healthcare budgets and bureaucratic pricing controls.The client realized that a "one-size-fits-all" global strategy would lead to significant delays in reimbursement, suboptimal pricing, and potential "price erosion" that could spill back into Western markets via reference pricing mechanisms.
With 15 years of deep-domain experience, Aditi Shivarkar uniquely merges advanced AI analytics with strategic industry insight. Her proven record in driving actionable intelligence and aligning emerging technologies with business focus positions her as the ideal expert to guide your AI transformation.
With 13 years of specialised industry experience, Aman Singh blends deep strategic vision with hands‑on AI insight. His track record in translating complex market intelligence into business‑ready strategies and aligning emerging analytics with operational focus positions him as the definitive partner for your requirements.
Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision, which enables us to achieve operational excellence, innovation, and sustained growth.
